Research ArticleArticle
Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy
Laura Durcan, Deborah A. Winegar, Margery A. Connelly, James D. Otvos, Laurence S. Magder and Michelle Petri
The Journal of Rheumatology February 2016, jrheum.150437; DOI: https://doi.org/10.3899/jrheum.150437
Laura Durcan
From the Johns Hopkins University School of Medicine, Baltimore; Department of Epidemiology and Public Health, University of Maryland, College Park, Maryland; LipoScience, Laboratory Corporation of America Holdings, Raleigh, North Carolina, USA. The Hopkins Lupus Cohort is supported by the US National Institutes of Health AR 43727. L. Durcan, MD, Johns Hopkins University School of Medicine; D.A. Winegar, PhD, LipoScience, Laboratory Corporation of America Holdings; M.A. Connelly, PhD, MBA, LipoScience, Laboratory Corporation of America Holdings; J.D. Otvos, PhD, LipoScience, Laboratory Corporation of America Holdings; L.S. Magder, MPH, PhD, Department of Epidemiology and Public Health, University of Maryland; M. Petri, MD, MPH, Johns Hopkins University School of Medicine. Address correspondence to Dr. L. Durcan, Johns Hopkins University School of Medicine, Rheumatology, 1830 East Monument St., Suite 7500, Baltimore, Maryland 21205, USA. E-mail: laurajanedurcan@hotmail.com. Accepted for publication December 11, 2015.
Deborah A. Winegar
From the Johns Hopkins University School of Medicine, Baltimore; Department of Epidemiology and Public Health, University of Maryland, College Park, Maryland; LipoScience, Laboratory Corporation of America Holdings, Raleigh, North Carolina, USA. The Hopkins Lupus Cohort is supported by the US National Institutes of Health AR 43727. L. Durcan, MD, Johns Hopkins University School of Medicine; D.A. Winegar, PhD, LipoScience, Laboratory Corporation of America Holdings; M.A. Connelly, PhD, MBA, LipoScience, Laboratory Corporation of America Holdings; J.D. Otvos, PhD, LipoScience, Laboratory Corporation of America Holdings; L.S. Magder, MPH, PhD, Department of Epidemiology and Public Health, University of Maryland; M. Petri, MD, MPH, Johns Hopkins University School of Medicine. Address correspondence to Dr. L. Durcan, Johns Hopkins University School of Medicine, Rheumatology, 1830 East Monument St., Suite 7500, Baltimore, Maryland 21205, USA. E-mail: laurajanedurcan@hotmail.com. Accepted for publication December 11, 2015.
Margery A. Connelly
From the Johns Hopkins University School of Medicine, Baltimore; Department of Epidemiology and Public Health, University of Maryland, College Park, Maryland; LipoScience, Laboratory Corporation of America Holdings, Raleigh, North Carolina, USA. The Hopkins Lupus Cohort is supported by the US National Institutes of Health AR 43727. L. Durcan, MD, Johns Hopkins University School of Medicine; D.A. Winegar, PhD, LipoScience, Laboratory Corporation of America Holdings; M.A. Connelly, PhD, MBA, LipoScience, Laboratory Corporation of America Holdings; J.D. Otvos, PhD, LipoScience, Laboratory Corporation of America Holdings; L.S. Magder, MPH, PhD, Department of Epidemiology and Public Health, University of Maryland; M. Petri, MD, MPH, Johns Hopkins University School of Medicine. Address correspondence to Dr. L. Durcan, Johns Hopkins University School of Medicine, Rheumatology, 1830 East Monument St., Suite 7500, Baltimore, Maryland 21205, USA. E-mail: laurajanedurcan@hotmail.com. Accepted for publication December 11, 2015.
James D. Otvos
From the Johns Hopkins University School of Medicine, Baltimore; Department of Epidemiology and Public Health, University of Maryland, College Park, Maryland; LipoScience, Laboratory Corporation of America Holdings, Raleigh, North Carolina, USA. The Hopkins Lupus Cohort is supported by the US National Institutes of Health AR 43727. L. Durcan, MD, Johns Hopkins University School of Medicine; D.A. Winegar, PhD, LipoScience, Laboratory Corporation of America Holdings; M.A. Connelly, PhD, MBA, LipoScience, Laboratory Corporation of America Holdings; J.D. Otvos, PhD, LipoScience, Laboratory Corporation of America Holdings; L.S. Magder, MPH, PhD, Department of Epidemiology and Public Health, University of Maryland; M. Petri, MD, MPH, Johns Hopkins University School of Medicine. Address correspondence to Dr. L. Durcan, Johns Hopkins University School of Medicine, Rheumatology, 1830 East Monument St., Suite 7500, Baltimore, Maryland 21205, USA. E-mail: laurajanedurcan@hotmail.com. Accepted for publication December 11, 2015.
Laurence S. Magder
From the Johns Hopkins University School of Medicine, Baltimore; Department of Epidemiology and Public Health, University of Maryland, College Park, Maryland; LipoScience, Laboratory Corporation of America Holdings, Raleigh, North Carolina, USA. The Hopkins Lupus Cohort is supported by the US National Institutes of Health AR 43727. L. Durcan, MD, Johns Hopkins University School of Medicine; D.A. Winegar, PhD, LipoScience, Laboratory Corporation of America Holdings; M.A. Connelly, PhD, MBA, LipoScience, Laboratory Corporation of America Holdings; J.D. Otvos, PhD, LipoScience, Laboratory Corporation of America Holdings; L.S. Magder, MPH, PhD, Department of Epidemiology and Public Health, University of Maryland; M. Petri, MD, MPH, Johns Hopkins University School of Medicine. Address correspondence to Dr. L. Durcan, Johns Hopkins University School of Medicine, Rheumatology, 1830 East Monument St., Suite 7500, Baltimore, Maryland 21205, USA. E-mail: laurajanedurcan@hotmail.com. Accepted for publication December 11, 2015.
Michelle Petri
From the Johns Hopkins University School of Medicine, Baltimore; Department of Epidemiology and Public Health, University of Maryland, College Park, Maryland; LipoScience, Laboratory Corporation of America Holdings, Raleigh, North Carolina, USA. The Hopkins Lupus Cohort is supported by the US National Institutes of Health AR 43727. L. Durcan, MD, Johns Hopkins University School of Medicine; D.A. Winegar, PhD, LipoScience, Laboratory Corporation of America Holdings; M.A. Connelly, PhD, MBA, LipoScience, Laboratory Corporation of America Holdings; J.D. Otvos, PhD, LipoScience, Laboratory Corporation of America Holdings; L.S. Magder, MPH, PhD, Department of Epidemiology and Public Health, University of Maryland; M. Petri, MD, MPH, Johns Hopkins University School of Medicine. Address correspondence to Dr. L. Durcan, Johns Hopkins University School of Medicine, Rheumatology, 1830 East Monument St., Suite 7500, Baltimore, Maryland 21205, USA. E-mail: laurajanedurcan@hotmail.com. Accepted for publication December 11, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy
Laura Durcan, Deborah A. Winegar, Margery A. Connelly, James D. Otvos, Laurence S. Magder, Michelle Petri
The Journal of Rheumatology Feb 2016, jrheum.150437; DOI: 10.3899/jrheum.150437
Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy
Laura Durcan, Deborah A. Winegar, Margery A. Connelly, James D. Otvos, Laurence S. Magder, Michelle Petri
The Journal of Rheumatology Feb 2016, jrheum.150437; DOI: 10.3899/jrheum.150437